Scarica l'app Stockscreener
0.85
2.30%
-0.02
Precedente Chiudi:
$0.87
Aprire:
$0.87
Volume 24 ore:
28,033
Relative Volume:
0.25
Capitalizzazione di mercato:
$20.54M
Reddito:
$411.00K
Utile/perdita netta:
$-4.85M
Rapporto P/E:
-1.9318
EPS:
-0.44
Flusso di cassa netto:
$-4.88M
1 W Prestazione:
-10.53%
1M Prestazione:
-16.67%
6M Prestazione:
-59.52%
1 anno Prestazione:
-69.20%
Intervallo 1D:
$0.847
$0.89
Intervallo di 1 settimana:
$0.82
$0.95
Portata 52W:
$0.82
$4.38
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Nome
Lexaria Bioscience Corp
Settore
Industria
Telefono
250-765-6424
Indirizzo
100 - 740 MCCURDY ROAD, KELOWNA
Confronta LEXX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.85 | 20.54M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp Borsa (LEXX) Ultime notizie
LEXX: GLP-1-H25-5 Study Complete - Yahoo Finance
Lexaria Bioscience announces completion of GLP-1-H25-5 study - Yahoo Finance
Lexaria’s Oral Liraglutide Shows Promise in Reducing Adverse Events - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results for Oral Liraglutide Study | LEXX Stock News - GuruFocus
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule | LEXX Stock News - GuruFocus
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule - TradingView
GLP-1 Breakthrough: Oral Liraglutide Shows 67% Less Nausea in Clinical Trial | LEXX Stock News - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Trading Up 4.3% – Still a Buy? - Defense World
Lexaria Bioscience to Engage with Industry Leaders at BIO International Convention - TipRanks
Lexaria Attending BIO International Convention | LEXX Stock News - GuruFocus
Lexaria Attending BIO International Convention - TradingView
Lexaria Targets Weight Loss and Diabetes Partnerships at Massive BIO Convention with 20,000 Attendees - Stock Titan
Lexaria Bioscience stock hits 52-week low at $0.94 By Investing.com - Investing.com South Africa
Lexaria Bioscience stock hits 52-week low at $0.94 - Investing.com
Lexaria Bioscience Corp (NASDAQ: LEXX) Is Down -15.79% Since Its Low, And It’s Only Getting Started. - Stocksregister
Lexaria advances drug delivery tech with PharmaCO By Investing.com - Investing.com Nigeria
Raymond James Financial Inc. Makes New Investment in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria (LEXX) Advances Collaborative Pharmaceutical Research | - GuruFocus
Lexaria Advances Collaboration with Pharma Partner on Drug Delivery Technology - TipRanks
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - marketscreener.com
Lexaria Provides Update on Material Transfer Agreement with Phar - GuruFocus
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Bioscience stock hits 52-week low at $1.14 By Investing.com - Investing.com India
Lexaria Bioscience stock hits 52-week low at $1.14 - Investing.com Australia
Lexaria Announces Closing of $2 Million Registered Direct Offeri - GuruFocus
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock - Yahoo Finance
Lexaria Bioscience Secures $2 Million in Direct Stock Offering - TipRanks
Lexaria Secures $2M Strategic Investment in Clean Direct Offering Amid Market Turbulence - Stock Titan
Market Watch Highlights: Lexaria Bioscience Corp (LEXX) Ends on an Downturn Note at 1.35 - DWinneX
Lexaria Bioscience Corp (LEXX) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
What is Zacks Small Cap’s Estimate for LEXX FY2025 Earnings? - Defense World
Lexaria Bioscience (LEXX) Announces $2M Direct Offering | LEXX S - GuruFocus
Lexaria Bioscience Secures $2 Million in Registered Direct Stock Offering - citybuzz -
Lexaria Announces $2 Million Registered Direct Offering of Commo - GuruFocus
Lexaria Bioscience secures $2 million in direct offering By Investing.com - Investing.com South Africa
Lexaria Bioscience secures $2 million in direct offering - Investing.com
Lexaria Announces $2 Million Registered Direct Offering of Common Stock - TradingView
Lexaria Lands $2M Strategic Investment: Institutional Investor Backs Biotech at $1.00 Per Share - Stock Titan
Lexaria Bioscience (OTCMKTS:LXRP) versus U.S. Gold (NASDAQ:USAU) Critical Comparison - Defense World
LEXXLexaria Bioscience Corp Latest Stock News & Market Updates - Stock Titan
LEXX: Second Quarter Results - Yahoo Finance
Lexaria Bioscience (LEXX) Advances in GLP-1 Technology Amid Indu - GuruFocus
Lexaria Bioscience Corp Azioni (LEXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexaria Bioscience Corp Azioni (LEXX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 02 '24 |
Buy |
2.24 |
22,828 |
51,217 |
22,828 |
| TURKEL CATHERINE C. | Director |
Aug 12 '24 |
Buy |
3.13 |
1,600 |
5,008 |
3,100 |
| Carle Vanessa | Secretary |
Jul 31 '24 |
Sale |
4.00 |
2,567 |
10,268 |
0 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):